Search Results

Her current work addresses one of the central unsolved problems in RAMP pharmacology: developing tools ligand contact Reproducibility and target validation as prerequisites for meaningful GPCR pharmacology Career in the final edited episode. 00:00 Welcome and episode announcements 01:40 Introduction - Hay 02:43 Career And it causes careers to die. Join me and learn more about Debbie’s career and what she learned through her experiences as a scientist

He had to decide, week by week, what could pause and what couldn't, and whose careers would bear the infrastructure as a substitute for physical proximity Chance and opportunity as drivers of a scientific career Gutkind reflects that the most significant advances in his career didn't come from confirming a premise pandemic 09:20 "Physical distancing, not social distancing" 11:31 Chance versus scientific knowledge in a career A large component of his work is centered around dysregulated signaling in cancer and the development

His lab develops BRET- and FRET-based biosensors that produce different conformational outputs depending His research centers on GPCR signaling networks, biosensor development, and the role of cellular context His lab develops resonance energy transfer-based biosensors and applies them in induced pluripotent stem Hebert's lab developed caged ligands that cross the plasma membrane and are uncaged intracellularly, His own career was shaped by serendipitous observations — GPCR dimers that no one expected, negative

. 💼 Job Board & Career Growth Helping researchers and biotech companies find the right opportunities Donate $25 $1,000 Catalyst Funds scholarships, retreats, and mentorship opportunities for early-career Help Us Close the Gap Between Academia and Biotech Together, we can accelerate GPCR discoveries and develop

and experimental systems (purified proteins, cultured cells, model organisms) in combination with the development Our ongoing efforts have direct implications in cancer, embryonic development defects, and neurological spans training in Spain, Belgium, and a postdoctoral fellowship at UC San Diego, where he navigated a career

David Tuveson at CSHL where he participated in the development of an organoid system for the culture normal and malignant pancreatic tissue, allowing advances in sequencing, target discovery and biomarker development He also continued his interest in computational analysis of cancer drivers by co-developing GECCO, an Career Trajectory and Faculty Position Yamina and Mike discussed Mike's career trajectory and his decision Mike shared his strategy of developing preliminary projects and gathering data to strengthen his application

At UCSF, he develops structural models of GPCRs using sparse experimental data - combining restraints to receptor pharmacology versus single-receptor studies Building scientific community at the early-career The failed experiment that built a career Bender's NPY2 labeling project - designed to generate DEER He articulates that the lateral connections formed at early-career conferences, between people who will 52:54 Bench fluency as a guard against over-interpreting computational models 58:16 Advice for early-career

to elucidate the role of steroidogenesis in regulating sexual determination and adrenal and gonadal development Caron has received numerous awards including a Burroughs Wellcome Fund Career Award in the Biomedical

Our goal is to deepen our understanding of GPCR function and accelerate the development of better therapies Accelerate — Intros, resources, and visibility that move projects and careers forward.

drug discovery moved from a stubborn crystallography problem to a generative platform — through the career 00 Welcome and guest introduction 02:32 How an undergraduate lecture on β-adrenergic signaling set a career One of her career path-defining moments came when she visited Dr. Chris Tate and Dr. co-founder of Heptares Therapeutics , now called Sosei Heptares , a GPCR-focused drug discovery and development Join me and learn more about her fascinating career trajectory. Dr.

That gap in care sparked a curiosity that became a career. He joined Mount Sinai through FlexMed — bypassing the MCAT — and was torn between a career in pharma Pivoting: Redefining the Pain Research Playbook Looking ahead, Serafini’s vision is bold: build a lab that develops He aspires to become a physician-scientist, with a focus on translational in vitro and in vivo model development Other academic interests of his include studying pharmaceutical finance & healthcare administration and developing

GPCR during COVID — the career arc behind the ecosystem built for the field's unreached receptors. << Her career has moved through academic pharmacology, a research fellowship in B-cell molecular immunology problem in GPCR drug discovery — why ~250 non-olfactory receptors remain outside clinical attention Career "Brian throughout his career was told so many times that he should quit science. About this episode GPCRs have played a central role in my scientific career ever since I took Dr.

cell surface proteins that mediate Wnt signaling — one of the most fundamental pathways in vertebrate development He began his scientific career studying adenosine receptor signaling during a PhD with Bertil Fredholm compound became the first pharmacological handle on frizzled SAG1.3, a small molecule agonist originally developed The development of a HEK cell line with all class F receptors knocked out — generated by Benoît Vanhollebeke's changed everything 53:43 Conformational change as the strongest argument for GPCR identity 01:03:11 Career

He currently leads Revvity's Research and Development activities, focusing on biochemical and cellular Before joining Revvity, Eric worked for Cisbio Bioassays first as Director of Technological Development screening to developing innovative solutions such as the IP-One kit for studying G Protein-Coupled Receptors department, leading her team on the development of innovative HTRF™ and AlphaLISA™ kits for pharma, Eric Trinquet, Director of Research and Development at Revvity.

receptors recycle from the lysosome, and the quantitative pharmacology that turned an early artifact into a career Follow the questions, not the career. Asked what advice she gives young scientists, Dr. Piñeyro's answer is blunt: she does not think of herself as having built a career. "I do not think I have a career. I was not building a career. I was simply following my interests." About this episode Dr.

Professor Sunahara started his independent research career in the Department of Pharmacology at the University One example of our recent work surrounds a structure-based effort to develop ligands that specifically Our goal is to develop safer beta2AR-selective ligands for the treatment of asthma and acute rescue therapy The Sunahara lab has also been developing protein-based therapeutics using structure-guided design and Through structural and computational approaches the Sunahara lab and collaborators developed a thermostable

The conversation also covers what happens when taste pharmacology intersects with drug development - ABOUT THE GUEST Masha Niv is associate professor and vice dean of research and development at the Hebrew Niv's lab developed a machine learning predictor trained on intensely bitter compounds that can flag bitterness risk from chemical structure alone, early in the development pipeline. Niv's lab is developing a recommendation system - trained on known receptor-ligand pairs and the structural

Along the way, he reflects on key career moments, the role of mentorship, and how curiosity continues where it still falls short Advice for junior scientists: what really matters when building a research career Should Listen GPCR scientists and pharmacologists Computational chemists and structural biologists Early-career That moment launched a career built around using computational tools to answer big biological questions

behind each transition: from chemistry to pharmacology, from membrane to endosome, from bench to product development The role is rarely discussed in academic career advising, yet it draws directly on GPCR pharmacology John Traynor , Kathryn worked to develop and understand first-in-class allosteric modulators of opioid There she researched the beta-2 adrenergic receptor and developed assays to investigate real-time activity Kathryn’s passion is developing solutions to problems in whatever form is most efficient: novel instrumentation

Explore a curated list of GPCR Courses to enhance your knowledge and career. until canceled Join Premium Now 🎓 Full GPCR University + 🔬 200+ expert talks 🗞️ Weekly research, careers matchmaking 💡 Support open resources for the global GPCR field 🧠 Designed for researchers at every career Aside from his vast experience in drug development, not to mention his extensive publication record, We have a 90% discount for people who live and work in developing countries and a 15% discount for team

She developed expertise over the past two decades studying structure/function relationships of GPCRs Sachdev is an early career researcher in the National Institute of Diabetes and Digestive and Kidney Her research centers on developing nanobody-ligand conjugates to target GPCRs, with a focus on receptors Driven by a passion for advancing drug development, John is committed to leveraging his expertise to Further down the track, he aims to apply this knowledge to develop novel chemical treatments for neuronal

Later in his career, Dr. Scientific Careers Depend on Teams, Mentors, and Community . 00 — Discovery of the prostaglandin EP4 receptor while searching for angiotensin-related sequences, development target discovery from association studies, and reflections on why many signals remained elusive. 52:00 — Career

study by crystallography, and the question of how to solve that became the organizing problem of his career His work developed the thermostabilization platform - a systematic approach to engineering receptor stability slightly from the final edited audio. 01:35 Meet Tate - membrane protein biochemist, MRC LMB 02:12 Career In 2005 he started working on the development of conformational thermostabilization of GPCRs, which resulted In 2016 mini-G proteins were developed as a tool for the structure determination of GPCRs in the fully

Aaron Sato, CSO of Twist Biopharma, describes the motif-directed library his team developed by collecting For Aaron, this work is personal: he has built his career hunting greenfield targets where others had His career has traced the evolution of antibody engineering, with leadership roles at DIAX, Oncomed, Aaron has a proven track record as a biologics leader as he led teams to discover and develop novel first-in-class

insightful experiences in academic, hospital, and industry labs, I decided to pursue a role in business development intersection of science and business, which includes target selection, preclinical strategy and business development to elucidate the role of steroidogenesis in regulating sexual determination and adrenal and gonadal development Caron has received numerous awards including a Burroughs Wellcome Fund Career Award in the Biomedical understand how the principles of receptor allosterism and functional selectivity can be leveraged in the development

Stroke Foundation of Canada MacDonald Scholar (1998-2003) and Heart and Stroke Foundation of Ontario Career His research career has focused on the investigation of the regulation of G protein-coupled receptors

Stroke Foundation of Canada MacDonald Scholar (1998-2003) and Heart and Stroke Foundation of Ontario Career His research career has focused on the investigation of the regulation of G protein-coupled receptors

. 🚀 Develop New GPCR Skills Join Dr. Terry Kenakin’s unique course, Development of GPCR Ligands as Therapeutic Drugs , and gain essential insights into: 🔹 Drug Development Basics – PK-PD insights, absorption, and drug properties 🔹 Clearance 🎧 Join Remi Janicot as he shares his educational journey, passion for basketball and science, and career He discusses biased signaling in GPCR research, developing biosensors for G protein activity, networking

academia, she co-founded two GPCR-focused biotechs with Heidi Hamm - CUE Biotech and Caden Biosciences - developing as a discipline shaped how she has thought about the relationship between target validation and drug development The peptides she developed - 11 amino acids rather than 55, which created their own detection challenges argument Biologics have a substantially higher success rate than small molecules moving through the drug development therapeutics an underexplored area - particularly for orphan GPCRs, where compounds are already being developed

opioid / dynorphin link The unfinished GPCR frontier — PACAP, CGRP, and the persistent antibody problem Career Earlier work in her career showed that high-internalizing delta agonists drive receptor downregulation A single collaboration can redirect a career. Her next career step took her to AstraZeneca as a postdoctoral trainee, where she studied animal models Her career path-defining moment came from a third postdoctoral experience with Dr.